Capricor Therapeutics, Inc. (CAPR) financial statements (2021 and earlier)

Company profile

Business Address 8840 WILSHIRE BLVD
BEVERLY HILLS, CA 90211
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments331071416148
Cash and cash equivalents33446368
Short-term investments 638138 
Restricted cash and investments  011 3
Receivables 000000
Other undisclosed current assets1111000
Total current assets:3411816181412
Noncurrent Assets
Property, plant and equipment1010000
Intangible assets, net (including goodwill)0000022
Intangible assets, net (excluding goodwill)0000022
Deferred costs     00
Other undisclosed noncurrent assets0000000
Total noncurrent assets:1111122
TOTAL ASSETS:3511916191614
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3111332
Other undisclosed accounts payable and accrued liabilities3111332
Debt0      
Deferred revenue and credits 144
Other undisclosed current liabilities 000000
Total current liabilities:3112576
Noncurrent Liabilities
Long-term debt and lease obligation0   1499
Long-term debt, excluding current maturities0   1499
Liabilities, other than long-term debt     14
Deferred revenue and credits  14
Other undisclosed noncurrent liabilities3333410
Total noncurrent liabilities:3333181114
Total liabilities:6455231720
Stockholders' equity
Stockholders' equity attributable to parent287511(4)(1)(6)
Common stock0000000
Additional paid in capital116817163503416
Accumulated other comprehensive income (loss) (0)0000 
Accumulated deficit(88)(74)(67)(52)(54)(35)(22)
Total stockholders' equity:287511(4)(1)(6)
TOTAL LIABILITIES AND EQUITY:3511916191614

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net1121
Gross profit:0123465
Operating expenses(14)(9)(17)(16)(21)(18)(11)
Operating loss:(14)(8)(15)(13)(17)(13)(6)
Nonoperating income (expense)00015(2)(0)(0)
Investment income, nonoperating0000000
Interest and debt expense   (0)(0)(0)(0)
Net income (loss):(14)(8)(15)2(19)(13)(6)
Other undisclosed net income attributable to parent   0000
Net income (loss) available to common stockholders, diluted:(14)(8)(15)2(19)(13)(6)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(14)(8)(15)2(19)(13)(6)
Comprehensive income (loss):(14)(8)(15)2(19)(13)(6)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)00000
Comprehensive income (loss), net of tax, attributable to parent:(14)(8)(15)2(19)(13)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: